

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human PIGF in direct ELISAs. In direct ELISAs, approximately 50% cross-reactivity with recombinant mouse PIGF-2 is observed.
Source	Polyclonal Sheep IgG
Purification	Antigen Affinity-purified
Immunogen	Chinese hamster ovary cell line CHO-derived recombinant human PIGF Leu19-Arg170 Accession # NP_002623
Conjugate	Alexa Fluor 594 Excitation Wavelength: 590 nm Emission Wavelength: 617 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide
*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.	

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Immunohistochemistry Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Placenta Growth Factor (PIGF) is a member of the Vascular Endothelial Growth Factor (VEGF) family of growth factors. PIGF and VEGF share primary structural as well as limited amino acid sequence homology with the A and B chains of PDGF. All eight cysteine residues involved in intra- and inter-chain disulfides are conserved among these growth factors. In their PDGF-like regions, VEGF and PIGF also share approximately 53% amino acid sequence similarity. The gene for PIGF has been mapped to chromosome 14. As a result of alternative splicing, at least two PIGF mRNAs encoding monomeric PIGF precursors containing 149 and 170 amino acid residues have been described. The expression of PIGF is not widespread, but has been detected in human umbilical vein endothelial cells, placenta, choriocarcinoma cell lines, and in renal cell carcinoma associated with angiogenesis. The PIGF proteins bind with high-affinity to Flt-1, but not to Flk-1/KDR.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.